Last updated 12 days ago
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation
498 patients around the world
Available in United States, Brazil, Spain
Genentech, Inc.
8Research sites
498Patients around the world
Requirements for the patient
From 18 Years
All Gender
Medical requirements
- Histologically documented advanced or metastatic solid tumor with KRAS G12C mutation.Women of childbearing potential must agree to remain abstinent or use contraception, and agree to refrain from donating eggs during the treatment period and after the final dose of study treatment as specified in the protocol.Men who are not surgically sterile must agree to remain abstinent or use a condom, and agreement to refrain from donating sperm during the treatment period and after the final dose of study treatment as specified in the protocol.
- Active brain metastases.Malabsorption or other condition that interferes with enteral absorption.Clinically significant cardiovascular dysfunction or liver disease.
Sites
Hospital Erasto Gaertner
Recruiting
Fundação Faculdade Regional de Medicina de São José do Rio Preto
Recruiting
Hospital Vall de Hebrón
Recruiting
Hospital Universitario Fundacion Jimenez Diaz
Recruiting
Hospital Universitario 12 de Octubre
Recruiting
Hospital Universitario Virgen de la Victoria
Recruiting
Hospital Uiversitario Virgen del Rocío
Recruiting
Hospital Clínico Universitario de Valencia
SponsorGenentech, Inc.
Study typeInterventional
Requirements
From 18 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT04449874
